You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study
|
|---|---|
| Published in |
Future Oncology, July 2021
|
| DOI | 10.2217/fon-2021-0427 |
| Pubmed ID | |
| Authors |
Shanu Modi |
X Demographics
The data shown below were collected from the profiles of 28 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 13 | 46% |
| Canada | 2 | 7% |
| United Kingdom | 2 | 7% |
| Unknown | 11 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 24 | 86% |
| Practitioners (doctors, other healthcare professionals) | 3 | 11% |
| Scientists | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 14% |
| Researcher | 7 | 14% |
| Student > Bachelor | 3 | 6% |
| Student > Ph. D. Student | 3 | 6% |
| Student > Master | 3 | 6% |
| Other | 6 | 12% |
| Unknown | 20 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 18% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Engineering | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 23 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 74. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2022.
All research outputs
#579,260
of 25,393,528 outputs
Outputs from Future Oncology
#27
of 2,464 outputs
Outputs of similar age
#15,037
of 446,143 outputs
Outputs of similar age from Future Oncology
#3
of 97 outputs
Altmetric has tracked 25,393,528 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,464 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,143 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.